Tema Oncology ETF CANC
42.10 USD +0.27 (+0.64%)
At closeNov 3, 2026, 4:00 PM EST
42.10 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
41.80 Day range 42.46
30.14 52-week range 47.00
- YTD
- +21.25%
- 1 year
- +37.31%
- Market cap
- 132.20M
- EPS (ttm)
- 1.59
- P/E ratio
- 26.48
- YTD return
- +21.25%
- 1-year return
- +37.31%
- Volume
- 13.72K
- Avg volume
- 24.14K
- Open
- 41.80
- Previous close
- 41.83
- Day's range
- 41.80 – 42.46
- 52-week range
- 30.14 – 47.00
1Y +11.81 (+38.81%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 27.30
- 200-day average
- 27.72
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
News
EXCLUSIVE: AI, Genomics Could Fuel Biotech ETF Re-Rating as Health Care Trades at Discount, Says Expert 
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough 
Biotech ETF (CANC) Hits New 52-Week High 
Tema ETFs Exceeds $5bn in AUM After Three Years 
Tema ETFs Surpasses $2 Billion in AUM in Under Three Years 
CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks 
Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application 
Tema Appoints ETF Industry Leader Steve Munroe as President 
Thrivent Financial for Lutherans Decreases Stake in Tema Oncology ETF $CANC 
Tema's Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance
Your note
Sign in to keep a note on CANC — it syncs with the Stock Master app.